多维度原发性肝癌实验诊断指标的临床应用  

Research update on the clinical application of multi-dimension laboratory markers in primary liver cancer

作　　者：黄晨军 高春芳 Huang Chenjun;Gao Chunfang(Clinical Research Center for Laboratory Medicine,Yue yang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai200437,China)

机构地区：[1]上海中医药大学附属岳阳中西医结合医院临床检验实验医学中心,上海200437

出　　处：《中华检验医学杂志》2025年第1期15-19,共5页Chinese Journal of Laboratory Medicine

基　　金：国家自然科学基金(82372321);上海市肿瘤分子医学协同创新项目(2019CXJQ03)。

摘　　要：在单一标志物无法满足原发性肝癌(PLC)临床诊疗需求的现状下,结合相关研究及指南共识,重点阐述GALAD、类GALAD(包括C-GALAD、C-GALADII、GALAD-C)模型和微小RNA组、糖蛋白糖组、乙型肝炎病毒基因组等多维度标志物在PLC的临床研究、应用进展和前景。对生物标志物的多维度综合分析,有助于精准辅助预测PLC高危风险、疾病诊断、疗效监测和预后判断等全程疾病管理。Single biomarker could not meet the clinical diagnostic and therapeutic needs in primary liver cancer(PLC)now.Based on the relevant researches and consensus from clinical guidelines,present review addresses the progress,application,and future prospects of multidimensional biomarkers,including models such as GALAD,GALAD-like algorithms(C-GALAD,C-GALADII,GALAD-C),microRNAs,glycoprotein glycome,and the hepatitis B virus genome in the clinical diagnostic and therapeutic applications.This review aims to illustrate the important practical significance of multidimensional application of biomarkers for high-risk prediction,disease diagnosis,therapeutic monitoring,and prognosis evaluation in the clinical management of PLC.

关 键 词：原发性肝癌 微RNA 糖组学 乙型肝炎病毒 基因组学 

分 类 号：R735.7[医药卫生—肿瘤]